Clinical Trial Update: UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. [EARLY_Phase 1]

View source ↗

Summary

UTAA09 Injection is being evaluated in an early Phase 1 trial for CD19-positive relapsed or refractory B-cell malignancies, with patient recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies
• Cd19-positive B-cell Malignancies

Drugs mentioned

• UTAA09

Snippet

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Conditions: CD19-positive Relapsed or Refractory B-cell Malignancies | EARLY_Phase 1 | Status: RECRUITING